Mankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix of debt and equity. This strategic move will make them ...
Free Press Journal on MSN1d
Mumbai: NGT Dismisses Pollution Allegations Against Bharat Serums' Ambernath Plant, Confirms Airoli Unit’s Compliance With Environmental StandardsMumbai: The National Green Tribunal (NGT) has dismissed allegations of water pollution against the Ambernath plant of Bharat ...
In a meeting held on December 20, 2024, the Fund Raising Committee of the company had approved the issue of 1.19 crore equity ...
The pharma company has acquired 100% stake in BSV for ₹13,768 crore, to be funded through a combination of internal accruals ...
3d
Mankind Pharma, India’s fourth-largest pharmaceutical company by domestic sales, has officially launched its Rs 3,000 crore ...
In one of the biggest deals in the pharmaceutical sector, Mankind Pharma on Thursday said it will fully acquire Bharat Serums and Vaccines from private equity investor Advent International for ...
Advent International has been present in India since 2007 and has committed over $6 billion in that time, spread across 19 ...
The indicative issue price for the QIP is expected to be approximately ₹2,520 per share, which could lead to an equity ...
The Competition Commission of India (CCI) has approved the acquisition of vaccine manufacturer Bharat Serums and Vaccines Ltd. by Mankind Pharma Ltd. This is reported in the CCI press release. In July ...
Mankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix of debt and equity. This strategic move will make them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback